These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 639175)

  • 21. Synthesis and characterization of a heterobifunctional photoaffinity reagent for modification of tryptophan residues and its application to the preparation of a photoreactive glucagon derivative.
    Demoliou CD; Epand RM
    Biochemistry; 1980 Sep; 19(20):4539-46. PubMed ID: 7426613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
    Xiao Q; Giguere J; Parisien M; Jeng W; St-Pierre SA; Brubaker PL; Wheeler MB
    Biochemistry; 2001 Mar; 40(9):2860-9. PubMed ID: 11258897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and hormonal activity of [Tyr22] glucagon and [desHis1, Tyr22] glucagon.
    Lu GS; Mojsov S; Merrifield RB
    Int J Pept Protein Res; 1987 Apr; 29(4):545-57. PubMed ID: 3454664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescent glucagon derivatives. I. Synthesis and characterisation of fluorescent glucagon derivatives.
    Heithier H; Ward LD; Cantrill RC; Klein HW; Im MJ; Pollak G; Freeman B; Schiltz E; Peters R; Helmreich EJ
    Biochim Biophys Acta; 1988 Oct; 971(3):298-306. PubMed ID: 2844291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re-evaluation of glucagon1-6: the N-terminal hexapeptide of glucagon is not biologically active in the hepatic adenylate cyclase system.
    Pelton JT; Trivedi D; Hruby VJ
    Life Sci; 1983 Sep; 33(13):1307-14. PubMed ID: 6888179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.
    Sarrauste de Menthière C; Chavanieu A; Grassy G; Dalle S; Salazar G; Kervran A; Pfeiffer B; Renard P; Delagrange P; Manechez D; Bakes D; Ktorza A; Calas B
    Eur J Med Chem; 2004 Jun; 39(6):473-80. PubMed ID: 15183905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary structures of glucagon and glucagon-like peptide isolated from the intestine of the parasitic phase lamprey Petromyzon marinus.
    Conlon JM; Nielsen PF; Youson JH
    Gen Comp Endocrinol; 1993 Jul; 91(1):96-104. PubMed ID: 8405897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
    Liepnieks JJ; Epand RM
    Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of glucagon partial agonists and antagonists.
    Gysin B; Trivedi D; Johnson DG; Hruby VJ
    Biochemistry; 1986 Dec; 25(25):8278-84. PubMed ID: 3814583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chicken glucagon: sequence and potency in receptor assay.
    Huang J; Eng J; Yalow RS
    Horm Metab Res; 1987 Nov; 19(11):542-4. PubMed ID: 2828209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properties of amidinated glucagons.
    Wright DE; Rodbell M
    Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.
    Andreu D; Merrifield RB
    Eur J Biochem; 1987 May; 164(3):585-90. PubMed ID: 3032623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selectively blocked and des-histidine-glucagons: preparation and effects on hepatic adenylate cyclase activity.
    Lande S; Gorman R; Bitensky M
    Endocrinology; 1972 Mar; 90(3):597-604. PubMed ID: 4333141
    [No Abstract]   [Full Text] [Related]  

  • 34. [25-oxindolylalanine]glucagon and [27-methionine sulfoxide]glucagon: preparation, purification, and characterization.
    Coolican SA; Jones BN; England RD; Flanders KC; Condit JD; Gurd RS
    Biochemistry; 1982 Sep; 21(20):4974-81. PubMed ID: 7138842
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems.
    Newswanger B; Ammons S; Phadnis N; Ward WK; Castle J; Campbell RW; Prestrelski SJ
    J Diabetes Sci Technol; 2015 Jan; 9(1):24-33. PubMed ID: 25550410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guinea pig glucagon differs from other mammalian glucagons.
    Huang CG; Eng J; Pan YC; Hulmes JD; Yalow RS
    Diabetes; 1986 May; 35(5):508-12. PubMed ID: 3956884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consideration of conformational transitions and racemization during process development of recombinant glucagon-like peptide-1.
    Senderoff RI; Kontor KM; Kreilgaard L; Chang JJ; Patel S; Krakover J; Heffernan JK; Snell LB; Rosenberg GB
    J Pharm Sci; 1998 Feb; 87(2):183-9. PubMed ID: 9519151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid.
    Heinrich G; Gros P; Lund PK; Bentley RC; Habener JF
    Endocrinology; 1984 Dec; 115(6):2176-81. PubMed ID: 6548696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roles of aspartic acid 15 and 21 in glucagon action: receptor anchor and surrogates for aspartic acid 9.
    Unson CG; Wu CR; Merrifield RB
    Biochemistry; 1994 Jun; 33(22):6884-7. PubMed ID: 8204623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of synthetic glucagon fragments on glucose-6-phosphate dehydrogenase. II.
    Abiko T; Kumikawa M; Sekino H
    Chem Pharm Bull (Tokyo); 1979 Nov; 27(11):2827-31. PubMed ID: 527148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.